Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PRO MEDICUS LIMITED Director's Dealing 2023

Mar 13, 2023

65579_rns_2023-03-13_f78adf8b-cc30-4721-9d25-f97c1dce5adc.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Listing Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Pro Medicus Limited ABN 25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Peter Terence KEMPEN
Date of last notice 21 February 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Ordinary fully paid shares in Pro Medicus
Limited
held
by
Elaine
Kempen
Superannuation Fund of which the Director is
a Trustee and Member
Date of change 7 March 2023
8 March 2023
9 March 2023
10 March 2023
13 March 2023
No. of securities held prior to change 679,082 ordinary shares consisting of: -

200,000 ordinary shares held under
Peter Terence KEMPEN

478,082 ordinary shares held under
Elaine Kempen Superannuation Fund
of which the Director is a Trustee and
Member

1,000 ordinary shares held under
EMK Investments Pty Ltd of which
the Director is a Director and
beneficial owner
Class Ordinary shares
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number acquired Nil
Number disposed 7 March 2023 – 10,000
8 March 2023 – 15,000
9 March 2023 – 11,389
10 March 2023 – 10,000
13 March 2023 – 3,611
Total – 50,000
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
7 March 2023 - $61.5691 per share
8 March 2023 - $62.1807 per share
9 March 2023 - $62.7975 per share
10 March 202 - $61.1922 per share
13 March 2023 - $61.2443 per share
No. of securities held after change 629,082 ordinary shares consisting of: -

200,000 ordinary shares held under
Peter Terence KEMPEN

428,082 ordinary shares held under
Elaine Kempen Superannuation Fund
of which the Director is a Trustee and
Member

1,000 ordinary shares held under
EMK Investments Pty Ltd of which
the Director is a Director and
beneficial owner
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
On market sales of shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the
trade to proceed during this period?
N/A
If prior written clearance was provided, on what date was
this provided?
N/A

For and on behalf of Pro Medicus Limited

==> picture [133 x 63] intentionally omitted <==

Clayton Hatch Company Secretary 14 March 2023

  • See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002